التفاصيل البيبلوغرافية
| العنوان: |
Abstract P238: US Cost Savings Resulting from the Dronedarone-Associated Reduction in Cardiovascular Hospitalizations among Atrial Fibrillation/Flutter Patients in the ATHENA Trial: Full Study Analysis |
| المؤلفون: |
Reynolds, Matthew, Zimetbaum, Peter J, Diamand, Françoise, Jhaveri, Mehul, Lin, Jay, Plich, Adam |
| المصدر: |
Circulation: Cardiovascular Quality and Outcomes ; volume 4, issue suppl_2 ; ISSN 1941-7713 1941-7705 |
| بيانات النشر: |
Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: |
2011 |
| الوصف: |
Introduction: The ATHENA trial randomized atrial fibrillation/flutter (AF/AFL) patients (pts) with ≥1 other cardiovascular (CV) risk factors to dronedarone (n=2301) or placebo (n=2327), plus standard care. Dronedarone reduced the rate of first CV hospitalization over the study period (mean ± SD 21 ± 5 months). This analysis assesses, from a US perspective, potential cost savings from the reduction in overall (first + subsequent) CV hospitalizations in ATHENA. Methods: Using a cost analysis model, we applied hospitalization costs reported from a US cohort of AF/AFL pts to hospitalization events among the ATHENA population. Clinical inputs included all CV- and adverse event (AE)-related hospitalizations over the ATHENA study period. Cost inputs (2008 values) were (i) weighted mean CV hospitalization costs (non-fatal + fatal combined), categorised according to cause of admission, derived from claims data for a cohort of ATHENA-like AF/AFL pts (n=10,200) with Medicare supplemental insurance, and (ii) DRG costs of hospitalizations for AEs recorded in ATHENA. Cost variations were assessed using Monte Carlo sensitivity analysis. Results: In ATHENA, overall CV hospitalization rate fell by 25% with dronedarone (1177/2301 vs 1596/2327, dronedarone vs placebo arms). Based on the observed hospitalization rates and derived hospitalization costs (Table), overall cost savings with dronedarone were estimated at (mean ± SD) $1763 ± 207 per pt over the ATHENA study period. The estimated savings in CV hospitalization costs (mean $1777 per pt) heavily outweighed the added estimated AE hospitalization costs (mean $14 per pt). Sensitivity analysis showed that the cost offset was relatively stable (range $1023−$2596 over 10,000 cycles of random variation). Conclusions: Dronedarone reduced the overall CV hospitalization rate by 25% in the ATHENA population, resulting in estimated mean hospitalization-related cost savings of $1763 per pt over the study period. Cause of hospitalization Number of hospitalizations per 100 patients 1 ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1161/circoutcomes.4.suppl_2.ap238 |
| الاتاحة: |
http://dx.doi.org/10.1161/circoutcomes.4.suppl_2.ap238 |
| رقم الانضمام: |
edsbas.7EBB335F |
| قاعدة البيانات: |
BASE |